At the time of writing, Adaptive Biotechnologies Corp [ADPT] stock is trading at $15.5, up 2.18%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADPT shares have gain 7.12% over the last week, with a monthly amount glided 22.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on September 30, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Craig Hallum started tracking the stock with Buy rating on June 18, 2025, and set its price target to $15. On March 21, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $15 as its price target on January 05, 2023. Piper Sandler upgraded its rating to Overweight for this stock on December 21, 2022, and upped its price target to $14. In a note dated August 25, 2022, Credit Suisse initiated an Underperform rating and provided a target price of $8 on this stock.
For the past year, the stock price of Adaptive Biotechnologies Corp fluctuated between $4.27 and $15.83. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $15.5 at the most recent close of the market. An investor can expect a potential return of 29.03% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
According to Adaptive Biotechnologies Corp [NASDAQ:ADPT], the company’s sales were 205.22M for trailing twelve months, which represents an 36.33% jump. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.61 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Adaptive Biotechnologies Corp [NASDAQ:ADPT] has a current ratio of 2.84. As well, the Quick Ratio is 2.75, while the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 11.50, the price to book ratio is 13.13.
Transactions by insiders
Recent insider trading involved PISKEL KYLE, Chief Financial Officer, that happened on May 16 ’25 when 1929.0 shares were sold. Chief Scientific Officer, ROBINS HARLAN S completed a deal on May 01 ’25 to sell 68412.0 shares. Meanwhile, Officer Harlan Robins bought 68412.0 shares on May 01 ’25.
